-
Posted by
Two Blokes Jul 4 -
Filed in
Stock
-
6 views
Medicus Pharma offers high-risk, high-reward potential with its novel SkinJect patch for basal cell carcinoma and recent Antev acquisition expanding its pipeline. Strong insider/institutional backing and leadership with skin in the game are positives, but ongoing heavy dilution and cash burn are major concerns. FDA approval for SkinJect and Antev's assets is at least two years away; revenue generation is unlikely before 2027-2028, requiring investor patience.
